Spiral Therapeutics Announces First Closing of a Series A Financing and Begins Phase 1 Trial of New Hearing Loss Drug
Hugo Peris, founder and Chief Executive Officer of Spiral Therapeutics

Spiral Therapeutics Announces First Closing of a Series A Financing and Begins Phase 1 Trial of New Hearing Loss Drug

  • December 31, 2018
  • News

Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, today announced the initiation of its Phase 1 clinical trial of LPT99, the company's lead investigational drug candidate targeting prevention…

Continue Reading

Spiral Therapeutics Begins Phase 1 Trial of Hearing Loss Drug

  • December 28, 2018
  • News

Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, announced the initiation of its Phase 1 clinical trial of LPT99, the company’s lead investigational drug candidate targeting prevention and treatment…

Continue Reading
Close Menu